Latest Oncology News

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

Chris Ryan

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

Kristi Rosa

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL

December 7th 2025

Ariana Pelosci

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

December 7th 2025

Jax DiEugenio

Decitabine/cedazuridine plus venetoclax produced a 91% response rate and 30-month median OS in high-risk MDS/CMML.

Teclistamab/Daratumumab Doublet Is Highly Effective and Tolerable for Elderly Patients With Transplant-Ineligible NDMM

December 7th 2025

Courtney Flaherty

The “all-antibody–based” doublet generated high VGPR or better rates and had a favorable safety profile in the front line for this patient population.

Latest Oncology Videos

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

43rd Annual Chemotherapy Foundation Symposium: The Show and After Show

Dr Scanlon on the Incidence, Management, and Physiologic Impact of IVC Tumor Thrombus in RCC

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer

Key Messages From the Breast Cancer ADC Data Set and Closing Remarks

Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast

Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer

Rechallenge Strategies, Practice Logistics, and Patient Communication Regarding ADCs in Breast Cancer

Selecting HER2 or TROP2 Directed ADCs in HER2 Low and Hormone Receptor Positive Breast Cancer

Supportive Care and Scheduling for Sacituzumab Govitecan in Clinical Practice in Breast Cancer

Clinical Impact of Datopotamab Deruxtecan in First Line Triple Negative Breast Cancer

CNS Recurrence and the Expanding Role of ADCs in Breast Cancer

Outcomes With Blinatumomab in Younger Adults With BCR:ABL1–negative B-ALL

Emerging Strategies for ALK+ NSCLC

Endometrial Cancer: Interpreting dMMR and Post-Adjuvant Activity from LEAP-001

Assessing Relapse: Clinical, Biological, and Patient-Centered Considerations

All Oncology News

Zanubrutinib Demonstrates Long-Term Efficacy, Safety in Relapsed/Refractory CLL/SLL

December 7th 2025

Kyle Doherty

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Pirtobrutinib Matches Ibrutinib in ORR, Shows Potential PFS Edge in BTK Inhibitor–Naive CLL/SLL

December 7th 2025

Jason Broderick

Pirtobrutinib yeilds superior overall response rates and promising progression-free survival compared to ibrutinib in chronic lymphocytic leukemia.

Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma

December 7th 2025

Gina Mauro

The addition of epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in relapsed/refractory follicular lymphoma.

Gintemetostat Shows Early Activity and Manageable Safety in Triple-Class Refractory Multiple Myeloma

December 7th 2025

Jason Broderick

Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

Epcoritamab Plus R-mini-CHOP May Aid in Treatment of Elderly Patients with First-Line DLBCL

December 7th 2025

Kristie L. Kahl

Epcoritamab plus R-mini-CHOP delivered deep responses with manageable safety in elderly, high-risk patients with newly diagnosed DLBCL.

Real-World Data Suggest ctDNA Status More Accurately Captures EFS Outcomes Than PET-CT

December 6th 2025

Caroline Seymour

ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.

Axatilimab Dosing Shift Shows Feasibility in cGVHD

December 6th 2025

Kristie L. Kahl

The AGAVE-201 trial showed successful transition from axatilimab 0.3 mg/kg biweekly to 0.6 mg/kg monthly in cGVHD.

Odronextamab Plus CHOP Produces Deep, Potentially Durable Responses in Previously Untreated DLBCL

December 6th 2025

Silas Inman

Early phase 3 data showed signals of efficacy with the addition of odronextamab to CHOP in patients with previously untreated DLBCL and high-risk features.

Rusfertide Continues to Show Strong Results for Polycythemia Vera

December 6th 2025

Silas Inman

Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile.

KRd Demonstrates Superior PFS vs VRd in Newly Diagnosed Myeloma

December 6th 2025

Jax DiEugenio

KRd improved PFS, deepened responses, and led to higher MRD negativity vs VRd in newly diagnosed multiple myeloma.

Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma

December 6th 2025

Chris Ryan

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple Myeloma

December 6th 2025

Kristi Rosa

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Survival in Induction Chemotherapy AML Studies May be Predictable by MRD

December 6th 2025

Russ Conroy

Future AML study analyses may focus on measurable residual disease to predict OS through non-intensive modern treatment backbones.

Race Is Predictive of Survival Outcomes With Intensive Chemotherapy Independent of Cytogenetics in AML

December 6th 2025

Bridget Hoyt

Findings from a retrospective analysis identified Black race as an independent predictor of inferior survival outcomes with intensive chemotherapy in AML.

Lisaftoclax Displays Activity in R/R CLL/SLL

December 6th 2025

Tony Berberabe, MPH

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

See All News